SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High – Still a Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $5.42 and last traded at $5.36, with a volume of 4998925 shares trading hands. The stock had previously closed at $5.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Stock Performance

The stock’s 50 day moving average is $4.07 and its 200 day moving average is $2.61. The company has a market capitalization of $743.54 million, a PE ratio of -18.64 and a beta of 2.18.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds have recently bought and sold shares of SLS. Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group during the third quarter valued at approximately $26,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at $26,000. BNP Paribas Financial Markets raised its position in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the period. Concurrent Investment Advisors LLC bought a new stake in SELLAS Life Sciences Group in the fourth quarter worth $38,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in SELLAS Life Sciences Group during the fourth quarter valued at about $38,000. Institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.